Biosynex SA
PAR:ALBIO

Watchlist Manager
Biosynex SA Logo
Biosynex SA
PAR:ALBIO
Watchlist
Price: 2.77 EUR -3.82% Market Closed
Market Cap: 29.8m EUR
Have any thoughts about
Biosynex SA?
Write Note

Biosynex SA
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Biosynex SA
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Biosynex SA
PAR:ALBIO
Current Portion of Long-Term Debt
€50.4m
CAGR 3-Years
108%
CAGR 5-Years
115%
CAGR 10-Years
62%
Edap Tms SA
NASDAQ:EDAP
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biomerieux SA
PAR:BIM
Current Portion of Long-Term Debt
€165.3m
CAGR 3-Years
0%
CAGR 5-Years
2%
CAGR 10-Years
5%
Carmat SA
PAR:ALCAR
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Visiomed Group SA
PAR:ALVMG
Current Portion of Long-Term Debt
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Amplitude Surgical SA
PAR:AMPLI
Current Portion of Long-Term Debt
€13.8m
CAGR 3-Years
17%
CAGR 5-Years
18%
CAGR 10-Years
N/A
No Stocks Found

Biosynex SA
Glance View

Market Cap
28.9m EUR
Industry
Health Care

Biosynex SA engages in the development, production, and distribution of Rapid Diagnostics Tests (RDTs) for pathologies. The company is headquartered in Illkirch-Graffenstaden, Grand Est. The company went IPO on 2011-03-21. The Company’s products are used by biological and analytical services laboratories, obstetric units and emergency units, as well as in medical resource-limited settings. Biosynex SA specializes in four fields: tropical diseases, emergency markers, infectious diseases and autoimmunity. The Company’s products include Amnioquick (Obstetrics); Immunoquick Malaria Falciparum and Immunoquick Malaria +4 (Parasitology); Immunoquick Elifa HSV IGG, Immunoquick Elifa EBV G and Immunoquick Mono (Virology); Immunoquick Filtration CELIAC IgA and Immunoquick TG (Autoimmunology); and Immunoquick Tetanus (Bacteriology). The company operates through Fumouze Diagnostics and SR2B.

ALBIO Intrinsic Value
7.73 EUR
Undervaluation 64%
Intrinsic Value
Price

See Also

What is Biosynex SA's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
50.4m EUR

Based on the financial report for Jun 30, 2024, Biosynex SA's Current Portion of Long-Term Debt amounts to 50.4m EUR.

What is Biosynex SA's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
62%

Over the last year, the Current Portion of Long-Term Debt growth was -5%. The average annual Current Portion of Long-Term Debt growth rates for Biosynex SA have been 108% over the past three years , 115% over the past five years , and 62% over the past ten years .

Back to Top